Of the 114 pancreatic cancer samples, 61 (54%) strongly expressed S145 phosphorylation of transgelin-2 and these patients had a median survival of only 9 months compared with 33 months in the 53 (46%) patients with weak staining (p = 0.004). This evidence concerns the gene TAGLN2 and pancreatic neoplasm.